Melanoma Market

Market Overview:

The 7 major melanoma markets reached a value of US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.9 Billion by 2034, exhibiting a growth rate (CAGR) of 7.93% during 2024-2034.

The melanoma market has been comprehensively analyzed in IMARC's new report titled "Melanoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Melanoma refers to a type of skin cancer that develops in the cells producing melanin, the pigment responsible for providing color to the skin, eyes, and hair. It can manifest in various ways, but most commonly, it appears as a new mole or a change in an existing mole. Several other potential symptoms of the ailment include the development of sores that do not heal; the appearance of new bumps or lumps under the skin; itchiness, tenderness, or pain in the affected area; etc. Melanoma is typically diagnosed through a combination of physical exams, imaging procedures, and biopsies. During a physical exam, a dermatologist or other healthcare provider will closely examine any mole or other marks on the skin to look for potential signs of melanoma. If a suspicious area is identified, various imaging tests, such as an MRI, CT scan, or  and PET scan, can be used to determine the extent of the cancer and if it has spread to other areas of the body. A biopsy is generally necessary to confirm a diagnosis of melanoma.

The increasing cases of exposure to ultraviolet radiation from the sun or tanning beds are primarily driving the melanoma market. Additionally, the rising incidence of several associated risk factors, such as having a large number of moles or atypical moles, fair skin that burns easily, weakened immune system, genetic mutations, etc., is also propelling the market growth. Besides this, the emerging popularity of intralesional therapy on account of its numerous benefits over systemic therapies, including targeted treatment, convenience, a lower risk of developing drug resistance, etc., is acting as another significant growth-inducing factor. Furthermore, the inflating adoption of reflectance confocal microscopy (RCM) for providing high-resolution images of the skin that can help identify the features of melanoma is also bolstering market growth. Apart from this, the escalating application of Mohs surgery for treating melanoma located on the face, hands, or feet, where preserving healthy tissue and minimizing scarring are especially important, further creates a positive outlook for the market. Moreover, the ongoing advancements in screening techniques, such as the introduction of dermoscopy and total body photography, which aid in improving the accuracy and efficiency of disease detection, are expected to drive the melanoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the melanoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for melanoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the melanoma market in any manner.

Recent Developments:

• In June 2024, Moderna and Merck presented the first results from a planned analysis from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 clinical trial study, evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection (n=157). With a median follow-up of three years (34.9 months), adjuvant treatment with mRNA-4157 in combination with KEYTRUDA continued to show a clinically meaningful and durable improvement in recurrence-free survival, the study's primary endpoint, lowering the risk of recurrence or death by 49% compared to KEYTRUDA alone.
• In February 2024, the Food and Drug Administration issued accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics), a tumor-derived autologous T cell immunotherapy, for adult individuals with unresectable or metastatic melanoma who had previously been treated with a PD-1 blocking antibody and, if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.

Key Highlights:

• According to the American Cancer Society, melanoma accounts for only 5% of skin cancer diagnoses, yet it causes the vast majority of skin cancer deaths.
• Melanoma is more common in white men than in white women, with incidence rates of 34.7 and 22.1 per 100,000, respectively.
• Melanoma is expected to affect 1 in 28 men and 1 in 41 women in their lifetime.
• Among Blacks, the male and female incidence was 1.0 and 0.9, respectively, while among Hispanics, both sexes had an incidence of 5.0.
• People's risk of developing melanoma increases with age. The average age upon diagnosis is 66.

Drugs:

COTELLIC is a prescription drug used in combination with ZELBORAF to treat melanoma that has spread to other parts of the body or cannot be removed surgically and has a specific type of faulty BRAF gene. The drug is a selective inhibitor that inhibits the activity of MEK, a protein kinase involved in the RAS-RAF-MEK-ERK pathway, which promotes cell division and survival. This pathway is commonly active in human malignancies, including melanoma, where a mutation in one of its components (BRAF) results in aberrant activation in approximately 50% of tumors.

KIMMTRAK is an innovative bispecific protein that combines a soluble T cell receptor with an anti-CD3 immune effector activity. KIMMTRAK targets gp100, a lineage antigen found in melanocytes and melanoma. This is the first chemical created using Immunocore's ImmTAC technology platform, which redirects and activates T lymphocytes to target and kill tumor cells.

The TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine is a one-of-a-kind type of immunotherapy due to its manufacturing and delivery methods. The vaccine is individualized, which means it is derived from the patient's tumor and blood. When TLPLDC is administered, the immune system receives the patient's entire repertoire of tumor antigens, resulting in a dual innate and adaptive immune response, activating fighter T cells, and triggering the immune system to recognize, seek out, and destroy any cells containing the antigens and specific mutations from their tumor.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the melanoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the melanoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current melanoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the melanoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the melanoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the melanoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of melanoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of melanoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of melanoma by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of melanoma by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with melanoma across the seven major markets?
• What is the size of the melanoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of melanoma?
• What will be the growth rate of patients across the seven major markets?
   

Melanoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for melanoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the melanoma market?
• What are the key regulatory events related to the melanoma market?
• What is the structure of clinical trial landscape by status related to the melanoma market?
• What is the structure of clinical trial landscape by phase related to the melanoma market?
• What is the structure of clinical trial landscape by route of administration related to the melanoma market?